ASH 2018 | A novel CD123-targeting antibody-drug conjugate for R/R AML
Daniel DeAngelo
• 2 Dec 2018
IMGN632 is a novel antibody-drug conjugate that targets CD123. Here, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the use of this agent in relapsed/refractory acute myeloid leukemia (AML) from the first-in-human study (NCT03386513). This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
